This business realignment will streamline internal efforts and is expected to extend the Company’s cash runway through at least the first quarter of 2024.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNTI:
- Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
- Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
- Senti Bio initiated with a Neutral at JPMorgan
- Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event